Translating CESD-20 and PHQ-9 Scores to PROMIS Depression

Kim, Jiseon; Chung, Hyewon; Askew, Robert L.; Park, Ryoungsun; Cook, Karon F.; Amtmann, Dagmar

doi:10.1177/1073191115607042

Cited by 36 publications

(28 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The PROMIS Depression instruments seem to be valid and reliable for measuring depressive symptoms [ 53 , 54 ]. Recent studies indicate that the PROMIS Depression CAT can be more easily used in clinical practice than the CES-D and PHQ-9 since it can be adapted to the needs in a specific care setting, while it results in comparable scores [ 55 – 57 ]. The PROMIS methodology is promising for use in patients with a chronic physical illness, minimizing the impact of somatic symptoms on depression scores while retaining enough uniformity to compare between patient populations and other depression measures [ 57 ].…”

Section: Discussionmentioning

confidence: 99%

Measurement properties of depression questionnaires in patients with diabetes: a systematic review

Dijk¹,

Adriaanse²,

Zwaan³

et al. 2018

Qual Life Res

View full text Add to dashboard Cite

PurposeTo conduct a systematic review on measurement properties of questionnaires measuring depressive symptoms in adult patients with type 1 or type 2 diabetes.MethodsA systematic review of the literature in MEDLINE, EMbase and PsycINFO was performed. Full text, original articles, published in any language up to October 2016 were included. Eligibility for inclusion was independently assessed by three reviewers who worked in pairs. Methodological quality of the studies was evaluated by two independent reviewers using the COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) checklist. Quality of the questionnaires was rated per measurement property, based on the number and quality of the included studies and the reported results.ResultsOf 6286 unique hits, 21 studies met our criteria evaluating nine different questionnaires in multiple settings and languages. The methodological quality of the included studies was variable for the different measurement properties: 9/15 studies scored ‘good’ or ‘excellent’ on internal consistency, 2/5 on reliability, 0/1 on content validity, 10/10 on structural validity, 8/11 on hypothesis testing, 1/5 on cross-cultural validity, and 4/9 on criterion validity. For the CES-D, there was strong evidence for good internal consistency, structural validity, and construct validity; moderate evidence for good criterion validity; and limited evidence for good cross-cultural validity. The PHQ-9 and WHO-5 also performed well on several measurement properties. However, the evidence for structural validity of the PHQ-9 was inconclusive. The WHO-5 was less extensively researched and originally not developed to measure depression.ConclusionCurrently, the CES-D is best supported for measuring depressive symptoms in diabetes patients.Electronic supplementary materialThe online version of this article (10.1007/s11136-018-1782-y) contains supplementary material, which is available to authorized users.

show abstract

Section: Discussionmentioning

confidence: 99%

Measurement properties of depression questionnaires in patients with diabetes: a systematic review

Dijk¹,

Adriaanse²,

Zwaan³

et al. 2018

Qual Life Res

View full text Add to dashboard Cite

show abstract

“…Also considered in models were time-varying covariates (TVC) which could alternate over time including body mass index (BMI) and self-reports of the following: use of non-steroidal anti-inflammatory drugs (NSAIDS) (yes or no), meeting the CDC guidelines for moderate/vigorous physical activity (MVPA) (yes or no) and depressive symptoms. Depressive symptoms (depression) at the T0, T1 and T2 time points were defined as having a Center for Epidemiologic Studies Depression (CES-D) score of 16; at the T3 time point depression was defined as having a Patient Reported Outcomes Measurement Information System Depression (PROMIS-D) score of 18 24 .…”

Section: Covariatesmentioning

confidence: 99%

The impact of painful knee osteoarthritis on mortality: a community-based cohort study with over 24 years of follow-up

Cleveland

Álvarez

Schwartz

et al. 2019

Osteoarthritis and Cartilage

View full text Add to dashboard Cite

s u m m a r yObjective: To investigate the impact of knee osteoarthritis (OA) and/or knee pain on excess mortality. Method: We analyzed data from 4,182 participants in a community-based prospective cohort study of African American and Caucasian men and women aged 45 years. Participants completed knee radiographs and questionnaires at baseline and at up to three follow-ups to determine knee OA (rOA), knee pain and covariate status. Mortality was determined through 2015. We used Cox proportional hazards regression with time-varying covariates (TVC) to estimate hazard ratios (HR) and 95% confidence intervals (CI). Additional analyses stratified by sex, race and age were carried out. Results: Median follow-up time was 14.6 years during which 1822 deaths occurred. Baseline knee radiographic osteoarthritis (rOA) was 27.7%, 38.8% at first follow-up, 52.6% at second follow-up and 61.9% at the third follow-up. Knee rOA with pain and knee pain alone were both associated with a >15% increase in premature all-cause mortality. In analyses stratified by sex, race and age, associations between knee pain, with or without knee rOA, and all-cause death were found among women, Caucasians, those 65 years of age, and those with a body mass index (BMI)30, with observed increased risks of death between 21% and 65%. We observed similar, somewhat attenuated, results for cardiovascular disease (CVD) deaths. Conclusion: In models taking into account variables that change over time, individuals who had knee pain, alone or with knee rOA, had increased mortality. These effects were particularly strong among those obese. Effective interventions to reduce knee pain, particularly those including weight management and prevention of comorbidities, could reduce mortality.

show abstract

“…Included studies were published between 2012 and 2017 by research groups based in the USA (n = 4) [18–21] and Canada(n = 3) [22–24]. Overall study quality was high (mean quality score 75%, range 62.5 to 93.8; Table 1).…”

Section: Resultsmentioning

confidence: 99%

“…Kim et al . [21] investigated the potential for PHQ-9 scores to be interpreted with respect to their equivalent PROMIS-D depression scores, estimating these through a process termed ‘cross-walking’. The correlation between the direct PROMIS-D score and the ‘cross-walked’ PHQ-9 was moderately strong at 0.74.…”

Section: Resultsmentioning

confidence: 99%

Psychometric properties of the PHQ-9 depression scale in people with multiple sclerosis: A systematic review

Patrick

Connick

2019

PLoS ONE

View full text Add to dashboard Cite

Background Depression affects approximately 25% of people with MS (pwMS) at any given time. It is however under recognised in clinical practice, in part due to a lack of uptake for brief assessment tools and uncertainty about their psychometric properties. The 9-item Patient Health Questionnaire (PHQ-9) is an attractive candidate for this role. Objective To synthesise published findings on the psychometric properties of the 9-item Patient Health Questionnaire (PHQ-9) when applied to people with multiple sclerosis (pwMS). Data sources PubMed, Medline and ISI Web of Science databases, supplemented by hand-searching of references from all eligible sources. Study eligibility criteria Primary literature written in English and published following peer-review with a primary aim to evaluate the performance of the PHQ-9 in pwMS. Outcome measures Psychometric performance with respect to appropriateness, reliability, validity, responsiveness, precision, interpretability, acceptability, and feasibility. Results Seven relevant studies were identified, these were of high quality and included 5080 participants from all MS disease-course groups. Strong evidence was found supporting the validity of the PHQ-9 as a unidimensional measure of depression. Used as a screening tool for major depressive disorder (MDD) with a cut-point of 11, sensitivity was 95% sensitivity and specificity 88.3% (PPV 51.4%, NPV 48.6%). Alternative scoring systems that may address the issue of overlap between somatic features of depression and features of MS per se are being developed, although their utility remains unclear. However data on reliability was limited, and no specific evidence was available on test-retest reliability, responsiveness, acceptability, or feasibility. Conclusions The PHQ-9 represents a suitable tool to screen for MDD in pwMS. However use as a diagnostic tool cannot currently be recommended, and the potential value for monitoring depressive symptoms cannot be established without further evidence on test-retest reliability, responsiveness, acceptability, and feasibility. Registration PROSPERO register ID: CRD42017067814 .

show abstract

Translating CESD-20 and PHQ-9 Scores to PROMIS Depression

Cited by 36 publications

References 22 publications

Measurement properties of depression questionnaires in patients with diabetes: a systematic review

Measurement properties of depression questionnaires in patients with diabetes: a systematic review

The impact of painful knee osteoarthritis on mortality: a community-based cohort study with over 24 years of follow-up

Psychometric properties of the PHQ-9 depression scale in people with multiple sclerosis: A systematic review

Contact Info

Product

Resources

About